Recent additions may not be included but will usually appear in 24 hrs or less.
| Rational | Source |
|---|---|
|
The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. ✅
Go to Publication ✅
Scientific reports (Sci Rep ) Vol: 8 Issue 1 Pages: 2964 Pub: 2018 Feb 14 Epub: 2018 Feb 14 Authors Sun YY , Li M , Li YY , Li LX , Zhai WZ , Wang P , Yang XX , Gu X , Song LJ , Li Z , Zuo XL , Li YQ , |
|
|
Clostridium butyricum regulates visceral hypersensitivity of irritable bowel syndrome by inhibiting colonic mucous low grade inflammation through its action on NLRP6. ✅
Go to Publication ✅
Acta biochimica et biophysica Sinica (Acta Biochim Biophys Sin (Shanghai) ) Vol: 50 Issue 2 Pages: 216-223 Pub: 2018 Feb 1 Epub: Authors Zhao K , Yu L , Wang X , He Y , Lu B , |
|
|
Gas chromatography/mass spectrometry based metabolomic study in a murine model of irritable bowel syndrome. ✅
Go to Publication ✅
World journal of gastroenterology (World J Gastroenterol ) Vol: 24 Issue 8 Pages: 894-904 Pub: 2018 Feb 28 Epub: Authors Yu LM , Zhao KJ , Wang SS , Wang X , Lu B , |
|
|
Clostridium butyricum alleviates intestinal low-grade inflammation in TNBS-induced irritable bowel syndrome in mice by regulating functional status of lamina propria dendritic cells. ✅
Go to Publication ✅
World journal of gastroenterology (World J Gastroenterol ) Vol: 25 Issue 36 Pages: 5469-5482 Pub: 2019 Sep 28 Epub: Authors Zhao Q , Yang WR , Wang XH , Li GQ , Xu LQ , Cui X , Liu Y , Zuo XL , |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.